Latest Breaking News On - பாரத் பயோடெக் சர்வதேச வரையறுக்கப்பட்டவை - Page 9 : comparemela.com

Highlights Hyderabad-based company claimed that it demonstrates overall vaccine efficacy of 77.8%. New Delhi: The Bharat Biotech on Saturday (July 3, 2021) released the results from the Phase 3 trials of Covaxin and claimed that it demonstrates overall vaccine efficacy of 77.8%. Over 25,798 participants were recruited between November 16, 2020, and January 7, 2021, and were randomised to Covaxin or placebo groups, of which, 24,419 received two doses of the vaccine.  In a case-driven analysis, 130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%) participants with follow-up at least two weeks after the second vaccination, whereas, 24 occurred in the vaccine group and 106 in placebo recipients giving an overall vaccine efficacy of 77.8%.  Sixteen cases, one vaccinee and 15 placebo recipients met the severe symptomatic COVID-19 case definition giving a vaccine efficacy of 93.4%. 

Andhra pradeshNew delhiKrishna ellaBalram bhargavaBharat biotech internationalIndian council of medical researchDepartment of health researchBharat biotechBharat biotech international limitedIndian councilMedical researchManaging directorSecretary departmentHealth researchDirector generalஆந்திரா பிரதேஷ்